Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Strategic Research Report

Scope of the Report

The global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market size is predicted to grow from US$ 150 million in 2025 to US$ 284 million in 2032; it is expected to grow at a CAGR of 9.3% from 2026 to 2032.

In 2025, global Anti-ANGPTL3 Antibody Lipid-lowering Drugs production reached approximately 19.19 K Units, with an average global market price of around 7988 USD per Unit.

Anti-ANGPTL3 Antibody Lipid-lowering Drugs is a monoclonal antibody designed to bind and inhibit angiopoietin-like protein 3 (ANGPTL3), a circulating liver-derived protein that regulates lipid metabolism by suppressing lipoprotein lipase (and related pathways). By neutralizing ANGPTL3’s activity, these antibodies aim to increase triglyceride-rich lipoprotein clearance and reduce atherogenic lipids (such as LDL cholesterol and triglycerides), and are used or developed for treating severe dyslipidemias and reducing cardiovascular risk.Evolocumab is the only marketed Anti-ANGPTL3 Antibody Lipid-lowering Drugs globally. It has been approved by the US FDA for the treatment of homozygous familial hypercholesterolemia (HoFH).

Anti-ANGPTL3 antibodies are compelling because they target a well-defined, liver-driven control point in lipid metabolism that can address a persistent industry pain point: a subset of patients remain at high cardiovascular risk despite today’s standard lipid-lowering options, either because of severe inherited dyslipidemias, mixed lipid abnormalities, intolerance, or residual risk that is not fully captured by LDL-centric approaches. By neutralizing ANGPTL3, these antibodies can reduce atherogenic lipoprotein burden through mechanisms that are complementary to statins and PCSK9 inhibitors, offering clinicians a differentiated tool when conventional pathways plateau and enabling a precision-medicine narrative for complex lipid phenotypes where triglycerides, remnants, and broader dyslipidemia matter. The category is being propelled by structural drivers that have reshaped cardiometabolic drug development: rising global prevalence of obesity and diabetes, stronger emphasis on preventing costly downstream events, increasing sophistication in genetic and biomarker-enabled patient identification, and growing confidence among payers and health systems in high-value biologics that demonstrate meaningful risk reduction in well-defined populations. Anti-ANGPTL3 antibodies have credible market runway as evidence and clinical experience mature, positioning expands from rare and refractory patients toward broader high-risk segments where unmet need remains, and combination strategies with established lipid therapies become more clearly standardized, making the class an attractive long-term opportunity within the evolving cardiometabolic landscape without relying on exaggerated claims.

The upstream raw materials for Anti-ANGPTL3 Antibody Lipid-lowering Drugs mainly include ANGPTL3 recombinant protein, CHO cells, etc. Typical raw material suppliers include Thermo Fisher, Merck, Pall, etc. The downstream application is mainly for people with high blood lipids.

The production capacity of Anti-ANGPTL3 Antibody Lipid-lowering Drugs production lines varies greatly depending on the type of drug molecule, process complexity, equipment scale, and production mode. The industry gross profit margin is usually in the range of 60%-80%.

Global key Anti-ANGPTL3 Antibody Lipid-lowering Drugs players cover Regeneron, Eli Lilly, Jiangsu Hengrui Medicine, Cspc Holdings, Suzhou Ribo Life Science, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market?

What factors are driving Anti-ANGPTL3 Antibody Lipid-lowering Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-ANGPTL3 Antibody Lipid-lowering Drugs market opportunities vary by end market size?

How does Anti-ANGPTL3 Antibody Lipid-lowering Drugs break out by Type, by Application?

This report presents a comprehensive overview of the global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Monoclonal Antibody
• Polyclonal Antibody
• Others

Segment by Mechanism of Action

• Direct Neutralization
• Indirect Inhibition

Segment by Route of Administration

• Intravenous Injection
• Subcutaneous Injection

Segment by Application

• Homozygous Familial Hypercholesterolaemia (HoFH)
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Homozygous Familial Hypercholesterolaemia (HoFH), Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact